Neutralny
Pfizer's stock price remains steady at $24.25 amid cautious analyst outlook.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
In the past 24 hours, there have been no significant developments affecting Pfizer's stock. The stock continues to trade at $24.25, reflecting a cautious market sentiment. Analysts maintain a 'Hold' rating, awaiting further catalysts to drive growth.
Kluczowe punkty
- Pfizer's stock price remains steady at $24.25, with no significant changes in the past 24 hours.
- Analysts continue to hold a 'Hold' rating on Pfizer, citing a cautious outlook due to recent pipeline setbacks.
- Investors are awaiting upcoming catalysts, such as the potential approval of sigvotatug vedotin for second-line lung cancer and mevro in the second half of 2026.
Źródła
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
